Sun Pharma approves ₹10,000 crore debt issuance
Sun Pharma approved ₹10,000 crore of NCD issuance through private placement in tranches, while independent director Gautam Doshi resigned immediately. OI Charts data showed the stock flat at ₹1,760, with key option levels at ₹1,780, ₹1,800 and ₹1,900.
pre-market1 source ↓machine-written, see hownot a recommendation
- SUNPHARMA close
- ₹1,760
- On the day
- 0.00%
- Futures OI, flat
- -0.6%
- Put-call ratio
- 0.71
- Max pain
- ₹1,800
Sun Pharma’s board approved raising ₹10,000 cr through non-convertible debentures on a private-placement basis, with the issuance planned in tranches. The company said the fundraising would strengthen its capital structure and optimise debt financing. On the same day, non-executive independent director Gautam Doshi resigned from the board with immediate effect.
The proposed borrowing is the key corporate-finance development for the pharmaceutical company 💊. Sun Pharma’s international issuer ratings stand at Baa1 from Moody’s and BBB+ from S&P Global, both with stable outlooks, according to the source. The board action therefore gives investors a defined funding plan to track, while the immediate director exit creates a separate governance disclosure for the market to assess. The article did not provide the interest rate, maturity, tranche schedule or intended allocation of the proceeds.
OI Charts data showed the stock at ₹1,760 on 12 Oct 2026, unchanged on the day, with volume of 1,141,685 shares. The stock had declined 1.1% over five sessions and 5.4% over 20 sessions, while remaining within its 52-week range of ₹1,584 to ₹2,047. Futures open interest fell 0.6% on the day and the contract traded at a 0.13% premium to the underlying, indicating limited change in derivatives positioning alongside the flat spot price.
In the options market, the put-call ratio was 0.71 for the 27 Oct 2026 expiry, which had 15 days remaining. The largest put open interest was at ₹1,780, close to the spot price, while the largest call open interest was at ₹1,900. Max pain stood at ₹1,800. These levels define the immediate derivatives reference points as traders await more detail on the fundraising and the board change
Next, investors will watch the company’s filing for the NCD coupon, maturity, tranche timing and use of funds, along with the stated reason for Doshi’s resignation. The ₹1,780 put-interest level, ₹1,800 max-pain level and ₹1,900 call-interest level are the key option-market markers before the 27 Oct expiry. Credit-market participants will also track whether the stable international ratings are reaffirmed after the issuance ⚖️.
Source: Sahi, 12 Oct 2026
Not investment advice. For informational purposes only.